Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Keywords
unspecified adult solid tumor, protocol specific, lung metastases, liver metastases
Brief summary
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
Detailed description
OBJECTIVES: * Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors. * Assess the toxicities of this treatment regimen in these patients. * Determine tumor response and cause of death in these patients treated with this regimen. OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Interventions
RADIATIONstereotactic radiosurgery
Sponsors
National Cancer Institute (NCI)
Virginia Commonwealth University
Study design
Allocation
NON_RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed malignancy * Extracranial recurrent or metastatic disease or primary tumor not predicted to be controlled with standard radiotherapy * Incurable with any standard therapy * No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or heart) * Tumor visible by CT scan PATIENT CHARACTERISTICS: Age: * Not specified Performance status: * Karnofsky 60-100% Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin less than 2.0 times upper limit of normal (ULN) * AST and ALT less than 5 times ULN Renal: * Creatinine less than 2.0 mg/dL Pulmonary: * FEV1 greater than 0.75 L Other: * No unsuitable size or geometric proportion that would preclude stereotactic immobilization * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 14 days since prior anticancer biologic therapy and recovered Chemotherapy: * At least 14 days since prior anticancer chemotherapy and recovered Endocrine therapy: * At least 14 days since prior anticancer endocrine therapy and recovered Radiotherapy: * See Disease Characteristics * At least 14 days since prior anticancer radiotherapy and recovered Surgery: * Not specified
Countries
United States
Outcome results
None listed